Tham khảo Ospemifene

  1. ↑ Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O (2003). “Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial”. Menopause. 10 (5): 433–9. doi:10.1097/01.GME.0000063609.62485.27. PMID 14501605.
  2. 1 2 3 4 Tanzi MG (tháng 4 năm 2013). “Ospemifene: New treatment for postmenopausal women”. Pharmacy Today. American Pharmacists Association.
  3. ↑ “FDA approves Osphena for postmenopausal women experiencing pain during sex”. FDA News Release. U.S. Food and Drug Administration. 26 tháng 2 năm 2013.
  4. ↑ “European Medicines Agency”.
  5. ↑ “Ospemifene: Indications, Side Effects, Warnings”. Drugs.com.
  6. ↑ “Shionogi Files a New Drug Application for Ospemifene Oral Tablets 60mg for the Treatment of Vulvar and Vaginal Atrophy”. Drugs.com.
  7. ↑ Kusiak V (13 tháng 2 năm 2013). “NDA Approval” (PDF). U.S. Food and Drug Administration.
  8. 1 2 Unkila M, Kari S, Yatkin E, Lammintausta R (tháng 11 năm 2013). “Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause”. J. Steroid Biochem. Mol. Biol. 138: 107–15. doi:10.1016/j.jsbmb.2013.04.004. PMID 23665515.
  9. ↑ Center for Drug Evaluation and Research (26 tháng 2 năm 2013). “Clinical Pharmacology and Biopharmaceutics Review Application Number 203505Orig1s000” (PDF). Office of Clinical Pharmacology Review. U.S. Food and Drug Administration.
  10. ↑ Bachmann GA, Komi JO (2010). “Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study”. Menopause. 17 (3): 480–6. doi:10.1097/gme.0b013e3181c1ac01. PMID 20032798.
  11. ↑ Portman DJ, Bachmann GA, Simon JA (tháng 6 năm 2013). “Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy”. Menopause. 20 (6): 623–30. doi:10.1097/gme.0b013e318279ba64. PMID 23361170.
  12. ↑ http://www.shionogi.co.jp/en/ir/pdf/e_p131101.pdf. First Half of Fiscal 2013 Financial Results. Nov. 1, 2013.
  13. ↑ http://www.thepharmaletter.com/article/fda-approves-shionogi-s-osphena-for-postmenopausal-women-experiencing-pain-during-sex. ThePharmaLetter

Tài liệu tham khảo

WikiPedia: Ospemifene http://www.chemspider.com/Chemical-Structure.23005... http://www.pharmacist.com/node/205934 http://www.thepharmaletter.com/article/fda-approve... http://www.ema.europa.eu/ema/index.jsp?curl=/pages... http://www.ema.europa.eu/en/medicines/human/EPAR/s... http://www.accessdata.fda.gov/drugsatfda_docs/appl... http://www.accessdata.fda.gov/drugsatfda_docs/nda/... http://www.fda.gov/NewsEvents/Newsroom/PressAnnoun... //pubmed.ncbi.nlm.nih.gov/14501605 //pubmed.ncbi.nlm.nih.gov/20032798